Not Signed In - Alexza Completes Enrollment In AZ-004 Phase IIa Clinical Trial In Schizophrenic Patients With Acute Agitation
Fri, 19 Jan 2007 08:00 AM EST
... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has completed patient enrollment in its Phase IIa clinical trial of AZ-004 (Staccato(R) loxapine). AZ-004 is an inhalation product candidate being developed for the acute treatment of agitation in schizophrenic patients. [click link for full article] ...
Related Topics
- Clinical Trials
- Acute Care
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Tarceva
- Wild Yam
- Vaccinations For HIV/AIDs Patients
- What Your Female Patients Want to Know About Bladder Control
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Smoking Cessation and Continued Risk in Cancer Patients
- Bevacizumab Injection
- Clinical Growth Charts
- Clinical Assessment Software Application
- Acute Coronary Syndrome
- Crohn's Disease
- Pancreatic Cancer
- Leukemia
- Patient Issues
email this page
print this page
bookmark this page
feedback on this page
